Daniel Skovronsky
Daniel Skovronsky is the Chief Scientific Officer at Eli Lilly and has been instrumental in advancing diabetes and obesity treatments. He recently highlighted the potential impact of a new oral GLP-1 medication, orforglipron, which could revolutionize treatment for millions suffering from type 2 diabetes and obesity.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Liechtenstein | 1 | 7.00 | 0.06% | +0% | 38,137 | 24 | $6,900 | 4$ |
| Totals | 1 | 38,137 | 24 | $6,900 | 4$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Liechtenstein:
Daniel Skovronsky, the scientific director of Lilly, stated that injections cannot be the solution for billions of people around the world.
7